|CLDX -- USA Stock|| |
USD 0.58 0.0066 1.12%
Founder, Chief Scientific Officer and Executive VP
Dr. Tibor Keler, Ph.D., serves as Executive Vice President and Chief Scientific Officer of Celldex Therapeutics Inc. since July 30, 2014. Since, May 2003, Dr. Keler has held a number of positions with Celldex, including a founder, Senior Vice President and Chief Scientific Officer of Celldex, from March 2008 to July 2014, and Vice President, Research and Discovery and Chief Scientific Officer, from May 2003 to March 2008. In addition, he was Senior Director of Preclinical Development and Principal Scientist at Medarex from September 1993 to March 2004. While at Medarex, he was responsible for the development of Celldex technology and products, as well as for the preclinical development and testing of numerous Medarex products now in clinical trials
Age: 57 Founder Since 2014 Ph.D
Keler received his Ph.D. in Microbiology from the University of Pennsylvania.
The company has return on total asset (ROA)
of (22.95) %
which means that it has lost $22.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (92.64) %
meaning that it created substantial loss on money invested by shareholders.
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc. Rockefeller University University of Southampton Amgen Inc. Amgen Fremont Seattle Genetics, Inc. Yale University and MedImmune, LLC. Celldex Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ. It employs 192 people.Celldex Therapeutics (CLDX) is traded on NASDAQ in USA. It is located in NEW JERSEY, U.S.A and employs 192 people. Celldex Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.
Celldex Therapeutics Leadership Team
|Theresa LaVallee, President, Ph.D|
|Keith Brownlie, Director|
|Ronald Pepin, SVP, Ph.D|
|Harry Penner, Director|
|Sam Martin, President, MBA|
|Karen Shoos, Director|
|Gerald McMahon, Director, Ph.D|
|Sarah Cavanaugh, President|
|Richard Broek, Director|
|Anthony Marucci, CEO, MBA|
|James Marino, Director, MBA|
|George Elston, Director|
|Thomas Davis, President|
|Avery Catlin, CFO, MBA|
|Richard Wright, President, MBA|
|Elizabeth Crowley, President|
|Larry Ellberger, Chairman|
|Herbert Conrad, Director|
|Margo HeathChiozzi, President|
|Tibor Keler, Founder, Ph.D|
Stock Performance Indicators
Most of Macroaxis users are currently bullish on Celldex Therapeutics. What is your opinion about investing in Celldex Therapeutics? Are you bullish or bearish?
and pair trading evaluation for Celldex Therapeutics and NantKwest
. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Check also Trending Equities
. Please also try Stock Tickers
module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.